|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Social Networking's 'Naked' Truth
- Geek Squad V. Gizmodo
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- WPP's Sir Martin Sorrell on the Ad Recession
- Four Things You Should Be Doing Now To Break Out
- Proprietary Trading May Cause October Crash: Investor
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
Swiss-based Roche said it was cutting production of influenza drug Tamiflu, seen as one of the best defences against a possible bird flu pandemic, because supply now exceeds demand.
The pharmaceutical group said it had increased capacity to more than 400 million treatments a year and that supply now significantly outstrips orders with signs of slowing sales to governments wanting to prepare for any outbreak.
The cutback would not affect Roche's expectations for sales of Tamiflu for stockpiling, at between 800 million Swiss francs ($665 million) to 1.2 billion francs ($1 billion) in 2007, said William Burns, head of the company's pharmaceuticals unit.
"Our guidance for the year is unchanged," Burns told reporters. "This is not a new signal on the sales outlook for Tamiflu."
Roche said the expansion of capacity meant it could now satisfy "significant additional orders" from governments and companies for Tamiflu.
Roche certificates, its most widely traded form of equity, were 0.5% lower at 232.30 francs in late trading.
The World Health Organization (WHO) and some countries have been stockpiling the drug in case the H5N1 bird flu strain, now mainly affecting poultry, mutates and begins to spread quickly among humans.
Roche will maintain its stock of intermediates and active pharmaceutical ingredients, so it would be ready to gear up to full production capacity if needed.
Sales to governments in the first quarter were slower than in the previous three months and Eugene Tierney, head of specialist sales at Roche's drugs unit, said that was the first indication of a tail off in government orders and demand.
The Basel-based company has so far received orders from governments amounting to about 215 million treatments.







